{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-125435","form_type":"8-K","ticker":"QTTB","cik":"0001661998","company_name":"Q32 Bio Inc.","filed_at":"2025-05-23T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.249298+00:00","generated_at":"2026-05-20T14:31:14.479666+00:00","sec_items":["3.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Q32 Bio receives Nasdaq delisting notice for stockholders' equity deficiency","bullets":["Stockholders' equity (deficit) of ~($4.0M) as of March 31, 2025, below Nasdaq's $2.5M minimum.","Also failed market value ($35M) and net income ($0.5M) alternatives.","Company has 45 calendar days to submit a plan to regain compliance; Nasdaq may grant up to 180 days.","Bempikibart-related liability of $55M from Amgen re-acquisition contributes to deficit.","No immediate effect on listing; stock continues trading under QTTB."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-125435","json":"https://secwatch.observer/filing/0001193125-25-125435.json","markdown":"https://secwatch.observer/filing/0001193125-25-125435.md","text":"https://secwatch.observer/filing/0001193125-25-125435.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1661998/000119312525125435/0001193125-25-125435-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1661998/000119312525125435/d842247d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-20T14:31:14.479666+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5435593a1601a53433208efdc491c68302b244c7","claim":"Q32 Bio Inc. received a nasdaq noncompliance notice notice regarding stockholders equity (rules 5550(b)(1), 5550(b)(2), 5550(b)(3)).","evidence_excerpt":"May 19, 2025, Q32 Bio Inc. (“Q32 Bio” or the “Company”) received written notice (the “Notice”) from the listing qualifications staff (the “Staff”) of the Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, based on the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2025 which reported the Company’s stockholders’ equity (deficit) of approximately ($4.0 million), the Company is no longer in compliance with the minimum stockholders’ equity requirement of $2.5 million for continued listing on the Nasdaq Capital Market per Listing Rule 5550(b)(1). Additionally, t","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1661998/000119312525125435/0001193125-25-125435-index.htm","confidence":0.9,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"noncompliance notice"},{"label":"Deficiency","value":"stockholders equity"},{"label":"Rules","value":"5550(b)(1), 5550(b)(2), 5550(b)(3)"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}